Ocular Therapeutix (OCUL) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ocular Therapeutix (OCUL) has outperformed uniQure N.V. (QURE) over the past year, losing 36.9% versus a loss of 62.4%. Over five years, QURE leads with a -25.0% price change compared with -32.9% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.66 billion vs $1.57 billion), about 1.1 times the size.
Ocular Therapeutix converts more of its revenue into profit, with a net margin of -511.9% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | QURE |
|---|---|---|
| Share price | $7.54 | $22.59 |
| Market cap | $1.66B | $1.57B |
| 1-day change | +0.40% | +0.22% |
| YTD return | -38.14% | -5.81% |
| 1-year return | -36.94% | -62.41% |
| 5-year return | -32.89% | -25.02% |
| EPS (TTM) | $-1.40 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $51.95M | $16.10M |
| Revenue growth (YoY) | -18.47% | -40.64% |
| Net income (latest FY) | $-265.94M | $-198.97M |
| Gross margin | 87.35% | 89.53% |
| Operating margin | -519.75% | -1151.38% |
| Net margin | -511.90% | -1236.00% |
| 52-week high | $16.44 | $71.50 |
| 52-week low | $6.23 | $8.73 |
| Distance from 52-week high | -54.14% | -68.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +259.28% | +175.92% |
| Average volume | 2.80M | 1.97M |
| Shares outstanding | 219.62M | 69.37M |
| Employees | 325 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OCUL has outperformed QURE by 25.5 percentage points over the past year.
- Ocular Therapeutix is more profitable, keeping -511.9 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Ocular Therapeutix grew revenue faster in its latest fiscal year (-18.47% vs -40.64%).
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
OCUL vs QURE FAQ
Which is bigger, Ocular Therapeutix or uniQure N.V.?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.66B compared with $1.57B for uniQure N.V. (QURE).
Which stock has performed better over the past year, OCUL or QURE?
OCUL returned -36.94% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.